Home/Pipeline/Dual-Targeting CAR-T Programs

Dual-Targeting CAR-T Programs

Oncology

Pre-clinicalActive

Key Facts

Indication

Oncology

Phase

Pre-clinical

Status

Active

Company

Factor Bioscience

About Factor Bioscience

Factor Bioscience is a private, pre-clinical stage biotechnology company developing a suite of foundational technologies for next-generation cell engineering. The company leverages its proprietary platforms in mRNA, gene editing (UltraSlice), and delivery to create cell therapies aimed at repairing mutations, conferring disease resistance, and enhancing immune cell function against cancer. With over 150 patents and a collaborative business model, Factor works with strategic partners to advance programs while also spinning out focused ventures like Exacis Biotherapeutics and Novellus Therapeutics.

View full company profile

Therapeutic Areas

Oncology Genetic Diseases Regenerative Medicine

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active